Johnson & Johnson (JNJ) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Johnson & Johnson's Executive VP and Worldwide Chairman of MedTech, Tim Schmid, is presenting at the 2025 Wells Fargo Healthcare Conference to discuss the $32 billion J&J MedTech business and the broader medical technology sector. Key discussions will center on the industry's growth outlook, specifically addressing whether the previously guided 5-7% sector growth rate remains valid, with Schmid initially affirming the industry's inherent attractiveness.

Analysis

At the 2025 Wells Fargo Healthcare Conference, Johnson & Johnson's Executive VP and Worldwide Chairman of MedTech, Tim Schmid, addressed the outlook for the medical technology sector. The discussion revisited the company's prior guidance from its 2023 Investor Day, which projected a 5% to 7% growth rate for the sector. While Schmid began his remarks by characterizing the MedTech industry as "highly attractive," signaling a continued optimistic stance, the provided transcript does not contain a definitive confirmation or revision of this specific growth forecast. The focus on this key metric highlights its importance for valuing JNJ's substantial $32 billion MedTech business. The overall sentiment is moderately positive, primarily driven by the optimistic framing from company leadership, though the market impact remains low as this represents an initial, incomplete segment of a broader strategic discussion.

Key Decisions for Investors

• Investors should monitor for the full transcript of the Q&A session to ascertain whether J&J leadership explicitly reaffirms, revises, or qualifies the 5% to 7% MedTech sector growth forecast, as this is a key benchmark for the industry.
• The confirmation of this growth outlook is a critical input for modeling the forward performance of JNJ's $32 billion MedTech division; any deviation could signal a shift in the company's or the industry's trajectory.
• Pay close attention to the second half of the discussion, which is slated to cover J&J MedTech-specific topics, for potential catalysts related to product innovation, M&A strategy, or margin improvement initiatives.